New Step by Step Map For P-gb-IN-1
MI-CP151 was a phase 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre study to evaluate many intravenous doses of sifalimumab, in adult clients with dermatomyositis or polymyositis (NCT00533091). Primary trial targets had been To guage the security and tolerability of sifalimumab in dermatomyositis or polymyositis indiv